Based upon these promising findings, ReNeuron is pursuing pre-clinical development of its selected exosome nanomedicine candidate, designated ExoPr0, targeting GBM. ReNeuron Group Plc has selected glioblastoma multiforme, the most common form of brain cancer, as the first clinical target for its ...
Read More »